Senescence; An endogenous anticancer mechanism

Frontiers in Bioscience

Volumn 17, Issue 7, 2011, Pages 2616-2643

  Vargas, Jose ^a   Feltes, Bruno Cesar ^b   De Faria Poloni, Joice ^b   Lenz, Guido ^a   Bonatto, Diego ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF CAXIAS DO SUL   (Brazil)

Author keywords

Cancer; Chemotherapy; DNA damage; Epigenetics; Evolution; Premature senescence; Replicative senescence; Review; Telomere erosion

Indexed keywords

EID: 84860273010     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4074     Document Type: Article

References (266)

1. D N Shelton, E Chang, P S Whittier, D Choi, W D Funk: Microarray analysis of replicative senescence. Curr Biol 9, 939-945 (1999) (Pubitemid 29442477)
2. K Nishio, A Inoue, S Qiao, H Kondo, A Mimura: Senescence and cytoskeleton: overproduction of vimentin induces senescent-like morphology in human fibroblasts. Histochem Cell Biol 116, 321-327 (2001) (Pubitemid 32972326)
3. D J Kurz, S Decary, Y Hong, J D Erusalimsky: Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113, 3613-3622 (2000)
4. R Zhang, W Chen, P D Adams: Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol 27, 2343-2358 (2007) (Pubitemid 46418486)
5. P D Adams: Remodeling of chromatin structure in senescent cells and its potential impact on tumor suppression and aging. Gene 397, 84-93 (2007) (Pubitemid 46992697)
6. LHayflick: The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37, 614-36 (1965)
7. W E Wright, J W Shay: Cellular senescence as a tumorprotection mechanism: the essential role of counting. Curr Opin Genet Dev 11, 98-103 (2001) (Pubitemid 32119285)
8. J W Shay, W E Wright: Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 26, 867-874 (2005) (Pubitemid 41214314)
9. J F Poyatos, A Carnero: Non-neutral role of replicative senescence in tissue homeostasis and tumorigenesis. J Theor Biol 230, 333-341 (2004) (Pubitemid 39092336)
10. J Campisi: Cancer and ageing: rival demons? Nat Rev Cancer 3, 339-349 (2003) (Pubitemid 37328854)
11. J P de Magalhaes, R G Faragher: Cell divisions and mammalian aging: integrative biology insights from genes that regulate longevity. Bioessays 30, 567-578 (2008) (Pubitemid 351859413)
12. K L MacKenzie, S Franco, C May, M Sadelain, M A Moore: Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Exp Cell Res 259, 336-350 (2000)
13. J W Shay, A F Gazdar: Telomerase in the early detection of cancer. J Clin Pathol 50, 106-109 (1997) (Pubitemid 27093024)
14. E H Blackburn, C W Greider, E Henderson, M S Lee, J Shampay, D Shippen-Lentz: Recognition and elongation of telomeres by telomerase. Genome 31, 553-560 (1989) (Pubitemid 20118437)
15. S E Artandi, R A DePinho: Telomeres and telomerase in cancer. Carcinogenesis 31, 9-18 (2010)
16. V G Gorgoulis, T D Halazonetis: Oncogene-induced senescence: the bright and dark side of the response. Curr Opin Cell Biol 22, 816-827 (2010)
17. C Chandeck, W J Mooi: Oncogene-induced cellular senescence. Adv Anat Pathol 17, 42-48 (2010)
18. S S Moumtzi, M L Roberts, T Joyce, M Evangelidou, L Probert, S Frillingos, T Fotsis, A Pintzas: Gene expression profile associated with oncogenic ras-induced senescence, cell death, and transforming properties in human cells. Cancer Invest 28, 563-587 (2010)
19. C J Sarkisian, B A Keister, D B Stairs, R B Boxer, S E Moody, L A Chodosh: Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9, 493-505 (2007) (Pubitemid 46696530)
20. L Mo, X Zheng, H Y Huang, E Shapiro, H Lepor, C Cordon-Cardo, T T Sun, X R Wu: Hyperactivation of Haras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 117, 314-325 (2007) (Pubitemid 46203960)
21. R Di Micco, M Fumagalli, A Cicalese, S Piccinin, P Gasparini, C Luise, C Schurra, M Garre, P G Nuciforo, A Bensimon, R Maestro, P G Pelicci, F d'Adda di Fagagna: Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638-642 (2006) (Pubitemid 44864443)
22. P Yaswen, J Campisi: Oncogene-induced senescence pathways weave an intricate tapestry. Cell 128, 233-234 (2007) (Pubitemid 46123519)
23. F Rodier, J P Coppe, C K Patil, W A Hoeijmakers, D P Munoz, S R Raza, A Freund, E Campeau, A R Davalos, J Campisi: Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11, 973-979 (2009)
24. C Nardella, J G Clohessy, A Alimonti, P P Pandolfi: Prosenescence therapy for cancer treatment. Nat Rev Cancer 11, 503-511 (2011)
25. Z Chen, L C Trotman, D Shaffer, H K Lin, Z A Dotan, M Niki, J A Koutcher, H I Scher, T Ludwig, W Gerald, C Cordon-Cardo, P P Pandolfi: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005) (Pubitemid 41117277)
26. J Blando, M Portis, F Benavides, A Alexander, G Mills, B Dave, C J Conti, J Kim, C L Walker: PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol 174, 1869-1879 (2009)
27. Z Chen, A Carracedo, H K Lin, J A Koutcher, N Behrendt, A Egia, A Alimonti, B S Carver, W Gerald, J Teruya-Feldstein, M Loda, P P Pandolfi: Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal 2, ra44 (2009)
28. M S Song, A Carracedo, L Salmena, S J Song, A Egia, M Malumbres, P P Pandolfi: Nuclear PTEN regulates the APCCDH1 tumor-suppressive complex in a phosphataseindependent manner. Cell 144, 187-199 (2011)
29. P Y Lin, S P Fosmire, S H Park, J Y Park, S Baksh, J F Modiano, R H Weiss: Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer 6, 16 (2007)
30. P Boffetta, F Nyberg: Contribution of environmental factors to cancer risk. Br Med Bull, 68, 71-94 (2003) (Pubitemid 38258221)
31. B C Dash, W S El-Deiry: Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol 280, 99-161 (2004)
32. C J Sherr: Cell cycle control and cancer. Harvey Lect 96, 73-92 (2000)
33. C J Sherr, R A DePinho: Cellular senescence: mitotic clock or culture shock? Cell 102, 407-410 (2000)
34. D A Alcorta, Y Xiong, D Phelps, G Hannon, D Beach, J C Barrett: Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A 93, 13742-13747 (1996) (Pubitemid 26424190)
35. F A Mallette, S Goumard, M F Gaumont-Leclerc, O Moieeva, G Ferbeyre: Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene 23, 91-99 (2004) . (Pubitemid 38142243)
36. D Hanahan, R A Weinberg: Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011)
37. K Egawa, Y Kurihara, T Ito, M Matsumoto, K Nose: Induction of p16INK4a transcription and of cellular senescence by aclacinomycin-derivatives and cardiac glycosides. Biol Pharm Bull 25, 461-465 (2002) (Pubitemid 40036736)
38. J Ewald, J Desotelle, N Almassi, D Jarrard: Druginduced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. Br J Cancer 98, 1244-1249 (2008) (Pubitemid 351481674)
39. J Bartkova, N Rezaei, M Liontos, P Karakaidos, D Kletsas, N Issaeva, L V Vassiliou, E Kolettas, K Niforou, V C Zoumpourlis, M Takaoka, H Nakagawa, F Tort, K Fugger, F Johansson, M Sehested, C L Andersen, L Dyrskjot, T Orntoft, J Lukas, C Kittas, T Helleday, T D Halazonetis, J Bartek, V G Gorgoulis: Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637 (2006) (Pubitemid 44864442)
40. R Di Micco G Sulli, M Dobreva, M Liontos, O A Botrugno, G Gargiulo, R dal Zuffo, V Matti, G d'Ario, E Montani, C Mercurio, W C Hahn, V Gorgoulis, S Minucci, F d'Adda di Fagagna: Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol, 13, 292-302 (2011)
41. F A Mallette, M F Gaumont-Leclerc, G Ferbeyre: The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 21, 43-48 (2007) (Pubitemid 46089705)
42. S H Kim Sh, P Kaminker, J Campisi: Telomeres, aging and cancer: in search of a happy ending. Oncogene 21, 503-511 (2002) (Pubitemid 34146250)
43. S W Chan, E H Blackburn: New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin. Oncogene 21, 553-563 (2002) (Pubitemid 34146255)
44. K A Mather, A F Jorm, R A Parslow, H Christensen: Is telomere length a biomarker of aging? A review. J Gerontol A Biol Sci Med Sci 66, 202-213 (2011)
45. Q Yang: Cellular senescence, telomere recombination and maintenance. Cytogenet Genome Res 122, 211-218 (2008)
46. J Meyne, R L Ratliff, R K Moyzis: Conservation of the human telomere sequence (TTAGGG)n among vertebrates. Proc Natl Acad Sci U S A 86, 7049-7053 (1989) (Pubitemid 19240864)
47. R K Moyzis, J M Buckingham, L S Cram, M Dani, L L Deaven, M D Jones, J Meyne, R L Ratliff, J R Wu: A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 85, 6622-6626 (1988)
48. E H Blackburn: Walking the walk from genes through telomere maintenance to cancer risk. Cancer Prev Res 4, 473-475 (2011)
49. S M Bailey, J P Murnane: Telomeres, chromosome instability and cancer. Nucleic Acids Res 34, 2408-2417 (2006) (Pubitemid 43985678)
50. M Chakhparonian, R J Wellinger: Telomere maintenance and DNA replication: how closely are these two connected? Trends Genet 19, 439-446 (2003) (Pubitemid 36930027)
51. M G Butler, J Tilburt, A DeVries, B Muralidhar, G Aue, L Hedges, J Atkinson, H Schwartz: Comparison of chromosome telomere integrity in multiple tissues from subjects at different ages. Cancer Genet Cytogenet 105, 138-144 (1998) (Pubitemid 28381628)
52. E S de Pauw, H Roelofs, A Zwinderman, J C van Houwelingen, W E Fibbe, P de Knijff, P L Pearson, H J Tanke: Studying the biological and technical sources of variation in telomere length of individual chromosomes. Cytometry A 65, 35-39 (2005) (Pubitemid 40604984)
53. T Suda, A Fujiyama, M Takimoto, M Igarashi, T Kuroiwa, N Waguri, H Kawai, Y Mita, Y Aoyagi: Interchromosomal telomere length variation. Biochem Biophys Res Commun 291, 210-214 (2002) (Pubitemid 34694391)
54. Y Deng, S S Chan, S Chang: Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 8, 450-458 (2008) (Pubitemid 351744962)
55. S E Artandi, R A DePinho: A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 10, 39-46 (2000) (Pubitemid 30113704)
56. N Ohtani, D J Mann, E Hara: Cellular senescence: its role in tumor suppression and aging. Cancer Sci 100, 792-797 (2009)
57. L E Donate, M A Blasco: Telomeres in cancer and ageing. Philos Trans R Soc Lond B Biol Sci 366, 76-84 (2011)
58. S T Yu, L Chen, H J Wang, X D Tang, D C Fang, S M Yang: hTERT promotes the invasion of telomerase negative tumor cells in vitro. Int J Oncol 35, 329-336 (2009)
59. C M Heaphy, A K Meeker: The potential utility of telomere-related markers for cancer diagnosis. J Cell Mol Med 15, 1227-1238 (2011)
60. P Martinez, M A Blasco: Role of shelterin in cancer and aging. Aging Cell 9, 653-666 (2010)
61. D M Feldser, C W Greider: Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11, 461-469 (2007) (Pubitemid 46670077)
62. W Cosme-Blanco, M F Shen, A J Lazar, S Pathak, G Lozano, A S Multani, S Chang: Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 8, 497-503 (2007) (Pubitemid 46696521)
63. S E Artandi, R A DePinho: Telomeres and telomerase in cancer. Carcinogenesis 31, 9-18 (2010)
64. P Willeit, J Willeit, A Mayr, S Weger, F Oberhollenzer, A Brandstatter, F Kronenberg, S Kiechl: Telomere length and risk of incident cancer and cancer mortality. JAMA 304, 69-75 (2010)
65. U Svenson, B Ljungberg, G Roos: Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. Cancer Res 69, 2896-2901 (2009)
66. L Mirabello, K Yu, P Kraft, I De Vivo, D J Hunter, J Prescott, J Y Wong, N Chatterjee, R B Hayes, S A Savage: The association of telomere length and genetic variation in telomere biology genes. Hum Mutat 31, 1050-1058 (2010)
67. E Rampazzo, R Bertorelle, L Serra, L Terrin, C Candiotto, S Pucciarelli, P Del Bianco, D Nitti, A De Rossi: Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers. Br J Cancer 102, 1300-1305 (2010)
68. S A Stewart, I Ben-Porath, V J Carey, B F O'Connor, W C Hahn, R A Weinberg: Erosion of the telomeric singlestrand overhang at replicative senescence. Nat Genet 33, 492-496 (2003) (Pubitemid 36390011)
69. Y Xu, T Ishizuka, K Kurabayashi, M Komiyama: Consecutive formation of G-quadruplexes in human telomeric-overhang DNA: a protective capping structure for telomere ends. Angew Chem Int Ed Engl 48, 7833-7836 (2009)
70. C W Greider: Telomeres do D-loop-T-loop. Cell 97, 419-422 (1999) (Pubitemid 29231163)
71. S Mattarocci, E D'Ambrosio, L Tafaro, V Somma, G Zannino, V Marigliano, F Ascenzioni, G Cimino-Reale: Erosion of telomeric 3'-overhangs in white blood cells of aged subjects with high frequency of very short telomeres. Mech Ageing Dev 132, 27-32 (2011)
72. D Rhodes, R Giraldo: Telomere structure and function. Curr Opin Struct Biol 5, 311-322 (1995)
73. F W Smith, J Feigon: Strand orientation in the DNA quadruplex formed from the Oxytricha telomere repeat oligonucleotide d(G4T4G4) in solution. Biochemistry 32, 8682-8692 (1993) (Pubitemid 23270456)
74. X Tian, B Chen, X Liu: Telomere and telomerase as targets for cancer therapy. Appl Biochem Biotechnol 160, 1460-1472 (2010)
75. M Folini, P Gandellini, N Zaffaroni: Targeting the telosome: therapeutic implications. Biochim Biophys Acta 1792, 309-316 (2009)
76. Q Yang, Y L Zheng, C C Harris: POT1 and TRF2 cooperate to maintain telomeric integrity. Mol Cell Biol 25, 1070-1080 (2005) (Pubitemid 40165813)
77. P Boukamp, N Mirancea: Telomeres rather than telomerase a key target for anti-cancer therapy? Exp Dermatol 16, 71-79 (2007) (Pubitemid 44890358)
78. S Gryaznov, A Asai, Y Oshima, Y Yamamoto, K Pongracz, R Pruzan, E Wunder, M Piatyszek, S Li, A Chin, C Harley, S Akinaga, Y Yamashita: Oligonucleotide N3'→ P5' thio-phosphoramidate telomerase template antagonists as potential anticancer agents. Nucleosides Nucleotides Nucleic Acids 22, 577-581 (2003) (Pubitemid 37139211)
79. J W Shay, W N Keith: Targeting telomerase for cancer therapeutics. Br J Cancer 98, 677-683 (2008) (Pubitemid 351272604)
80. L Kelland: Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin Cancer Res 13, 4960-4963 (2007) (Pubitemid 47502059)
81. Z G Dikmen, G C Gellert, S Jackson, S Gryaznov, R Tressler, P Dogan, W E Wright, J W Shay: In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 65, 7866-7873 (2005) (Pubitemid 41297263)
82. S R Jackson, C H Zhu, V Paulson, L Watkins, Z G Dikmen, S M Gryaznov, W E Wright, J W Shay: Antiadhesive effects of GRN163L-an oligonucleotide N3'→P5' thio-phosphoramidate targeting telomerase. Cancer Res 67, 1121-1129 (2007)
83. C B Harley: Telomerase and cancer therapeutics. Nat Rev Cancer 8, 167-179 (2008) (Pubitemid 351305939)
84. G C Gellert, Z G Dikmen, W E Wright, S Gryaznov, J W Shay: Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 96, 73-81 (2006)
85. A E Hochreiter, H Xiao, E M Goldblatt, S M Gryaznov, K D Miller, S Badve, G W Sledge, B S Herbert: Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 12, 3184-3192 (2006) (Pubitemid 43837368)
86. J Gomez-Millan, E M Goldblatt, S M Gryaznov, M S Mendonca, B S Herbert: Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. Int J Radiat Oncol Biol Phys 67, 897-905 (2007) (Pubitemid 46215875)
87. M W Djojosubroto, A C Chin, N Go, S Schaetzlein, M P Manns, S Gryaznov, C B Harley, K L Rudolph: Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 42, 1127-1136 (2005) (Pubitemid 43112680)
88. T Ozawa, S M Gryaznov, L J Hu, K Pongracz, R A Santos, A W Bollen, K R Lamborn, D F Deen: Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro Oncol, 6, 218-226 (2004) (Pubitemid 39136505)
89. M Akiyama, T Hideshima, M A Shammas, T Hayashi, M Hamasaki, Y T Tai, P Richardson, S Gryaznov, N C Munshi, K C Anderson: Effects of oligonucleotide N3'- > P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 63, 6187-6194 (2003) (Pubitemid 37255162)
90. S K Brennan, Q Wang, R Tressler, C Harley, N Go, E Bassett, C A Huff, R J Jones, W Matsui: Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 5, e12487 (2010)
91. M Dean, T Fojo, S Bates: Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284 (2005) (Pubitemid 40488633)
92. V Brower: Telomerase-based therapies emerging slowly. J Natl Cancer Inst 102, 520-521 (2010)
93. P E Nielsen, M Egholm, R H Berg, O Buchardt: Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254, 1497-1500 (1991) (Pubitemid 21917487)
94. J C Norton, M A Piatyszek, W E Wright, J W Shay, D R Corey: Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotechnol 14, 615-619 (1996) (Pubitemid 26135126)
95. M A Shammas, C G Simmons, D R Corey, R J Shmookler Reis: Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells. Oncogene 18, 6191-6200 (1999)
96. S E Hamilton, C G Simmons, I S Kathiriya, D R Corey: Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem Biol 6, 343-351 (1999) (Pubitemid 29363167)
97. I Tarkanyi, J Aradi: Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease. Biochimie 90, 156-172 (2008) (Pubitemid 350216216)
98. H Qi, C P Lin, X Fu, L M Wood, A A Liu, Y C Tsai, Y Chen, C M Barbieri, D S Pilch, L F Liu: G-quadruplexes induce apoptosis in tumor cells. Cancer Res 66, 11808-11816 (2006) (Pubitemid 46094192)
99. F Riou, L Guittat, P Mailliet, A Laoui, E Renou, O Petitgenet, F Megnin-Chanet, C Helene, J L Mergny: Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc Natl Acad Sci U S A 99, 2672-2677 (2002) (Pubitemid 34240519)
100. T Tauchi, K Shin-Ya, G Sashida, M Sumi, A Nakajima, T Shimamoto, J H Ohyashiki, K Ohyashiki: Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 22, 5338-5347 (2003) (Pubitemid 37056096)
101. C M Incles, C M Schultes, H Kempski, H Koehler, L R Kelland, S Neidle: A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells. Mol Cancer Ther 3, 1201-1206 (2004) (Pubitemid 39440164)
102. C Leonetti, S Amodei, C D'Angelo, A Rizzo, B Benassi, A Antonelli, R Elli, M F Stevens, M D'Incalci, G Zupi, A Biroccio: Biological activity of the G-quadruplex ligand RHPS4 (3, 11-difluoro-6, 8, 13-trimethyl-8H-quino[4, 3, 2-kl]acridinium methosulfate) is associated with telomere capping alteration. Mol Pharmacol 66, 1138-1146 (2004) (Pubitemid 39411054)
103. N Temime-Smaali, L Guittat, A Sidibe, K Shin-ya, C Trentesaux, J F Riou: The G-quadruplex ligand telomestatin impairs binding of topoisomerase IIIalpha to G-quadruplexforming oligonucleotides and uncaps telomeres in ALT cells. PLoS One 4, e6919 (2009)
104. S A Stewart, W C Hahn, B F O'Connor, E N Banner, A S Lundberg, P Modha, H Mizuno, M W Brooks, M Fleming, D B Zimonjic, N C Popescu, R A Weinberg: Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 99, 12606-12611 (2002)
105. S M Gowan, J R Harrison, L Patterson, M Valenti, M A Read, S Neidle, L R Kelland: A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 61, 1154-1162 (2002) (Pubitemid 34441781)
106. H Tahara, K Shin-Ya, H Seimiya, H Yamada, T Tsuruo, T Ide: G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells. Oncogene 25, 1955-1966 (2006)
107. H Cheng, Z Wu, J Zheng, G Lu, J Yan, M Liu, D Huang, J Lin: Inhibition on telomerase activity and cytotoxic effects by cisplatin in cultured human choroidal melanoma cells. Yan Ke Xue Bao 19, 54-59 (2003)
108. D Sadava, E Whitlock, S E Kane: The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun 360, 233-237 (2007) (Pubitemid 46994711)
109. S Hayakawa, K Saeki, M Sazuka, Y Suzuki, Y Shoji, T Ohta, K Kaji, A You, M Isemura: Apoptosis induction by epigallocatechin gallate involves its binding to Fas. Biochem Biophys Res Commun 285, 1102-1106 (2001) (Pubitemid 32912894)
110. Q Meng, C N Velalar, R Ruan: Effects of epigallocatechin-3-gallate on mitochondrial integrity and antioxidative enzyme activity in the aging process of human fibroblast. Free Radic Biol Med 44, 1032-1041 (2008)
111. N E Sharpless, R A DePinho: Telomeres, stem cells, senescence, and cancer. J Clin Invest 113, 160-168 (2004) (Pubitemid 38544198)
112. Guittat, P Alberti, D Gomez, A De Cian, G Pennarun, T Lemarteleur, C Belmokhtar, R Paterski, H Morjani, C Trentesaux, E Mandine, F Boussin, P Mailliet, L Lacroix, J F Riou, J L Mergny: Targeting human telomerase for cancer therapeutics. Cytotechnology 45, 75-90 (2004) (Pubitemid 40568825)
113. E Pascolo, C Wenz, J Lingner, N Hauel, H Priepke, I Kauffmann, P Garin-Chesa, W J Rettig, K Damm, A Schnapp: Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 277, 15566-15572 (2002) (Pubitemid 34967825)
114. G Lenz: The RNA interference revolution. Braz J Med Biol Res 38, 1749-1757 (2005) (Pubitemid 43078604)
115. X Qian, J Cheng, A Chen, Y Wang, Y Tao, J Cao, Z Feng: Long-term effects of short hairpin RNA-targeted human telomerase reverse transcriptase on suppression of SGC-7901 cell proliferation by inhibition of telomerase activity. Oncol Rep 19, 575-581 (2008) (Pubitemid 351176123)
116. A Shammas, H Koley, R B Batchu, R C Bertheau, A Protopopov, N C Munshi, R K Goyal: Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer 4, 24 (2005)
117. P H Zhang, L Zou, Z G Tu: RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J Surg Res 131, 143-149 (2006) (Pubitemid 43227598)
118. X Dong, A Liu, C Zer, J Feng, Z Zhen, M Yang, L Zhong: siRNA inhibition of telomerase enhances the anticancer effect of doxorubicin in breast cancer cells. BMC Cancer 9, 133 (2009)
119. L Zou, P Zhang, C Luo, Z Tu: shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother Pharmacol 57, 328-334 (2006)
120. X Liu, H Huang, J Wang, C Wang, M Wang, B Zhang, C Pan: Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol 82, 17-23 (2011)
121. P Spallarossa, P Altieri, C Aloi, S Garibaldi, C Barisione, G Ghigliotti, G Fugazza, A Barsotti, C Brunelli: Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol 297, H2169-H2181 (2009)
122. A Sfeir, S T Kosiyatrakul, D Hockemeyer, S L MacRae, J Karlseder, C L Schildkraut, T de Lange: Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell 138, 90-103 (2009)
123. P Zhang, K Furukawa, P L Opresko, X Xu, V A Bohr, M P Mattson: TRF2 dysfunction elicits DNA damage responses associated with senescence in proliferating neural cells and differentiation of neurons. J Neurochem 97, 567-581 (2006)
124. L Wu, A S Multani, H He, W Cosme-Blanco, Y Deng, J M Deng, O Bachilo, S Pathak, H Tahara, S M Bailey, R R Behringer, S Chang: Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 126, 49-62 (2006)
125. A M Burger, F Dai, C M Schultes, A P Reszka, M J Moore, J A Double, S Neidle: The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res 65, 1489-1496 (2005) (Pubitemid 40270178)
126. P Phatak, J C Cookson, F Dai, V Smith, R B Gartenhaus, M F Stevens, A M Burger: Telomere uncapping by the Gquadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer 96, 1223-1233 (2007) (Pubitemid 46625068)
127. W J Zhou, R Deng, X Y Zhang, G K Feng, L Q Gu, X F Zhu: G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells. Mol Cancer Ther 8, 3203-3213 (2009)
128. C O Marian, S K Cho, B M McEllin, E A Maher, K J Hatanpaa, C J Madden, B E Mickey, W E Wright, J W Shay, R M Bachoo: The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 16, 154-163 (2010)
129. I Joseph, R Tressler, E Bassett, C Harley, C M Buseman, P Pattamatta, W E Wright, J W Shay, N F Go: The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 70, 9494-9504 (2010)
130. W Djojosubroto, A C Chin, N Go, S Schaetzlein, M P Manns, S Gryaznov, C B Harley, K L Rudolph: Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 42, 1127-1136 (2005) (Pubitemid 43112680)
131. S Mueller, U Hartmann, F Mayer, S Balabanov, J T Hartmann, T H Brummendorf, C Bokemeyer: Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors. Invest New Drugs 25, 519-524 (2007)
132. S M Chen, Z Z Tao, Q Q Hua, D Liu, H M Chi, Q Cai: Inhibition of human telomerase reverse transcriptase in hep-2 cells using short hairpin RNA expression vectors. Arch Otolaryngol Head Neck Surg 132, 200-205 (2006) (Pubitemid 43356259)
133. L Teng, M C Specht, C B Barden, T J Fahey, 3rd: Antisense hTERT inhibits thyroid cancer cell growth. J Clin Endocrinol Metab 88, 1362-1366 (2003) (Pubitemid 36337801)
134. L Chen, Y Hu, W P Shuai, H L Chen, W Q Liang, J Q Gao: Telomerase-targeting antisense oligonucleotides carried by polycation liposomes enhance the growth inhibition effect on tumor cells. J Biomed Mater Res B Appl Biomater 89B, 362-368 (2009)
135. P Paulasova, F Pellestor: The peptide nucleic acids (PNAs): a new generation of probes for genetic and cytogenetic analyses. Ann Genet 47, 349-358 (2004) (Pubitemid 39575613)
136. V Urquidi, D Tarin, S Goodison: Role of telomerase in cell senescence and oncogenesis. Annu Rev Med 51, 65-79 (2000) (Pubitemid 30216026)
137. J D Henson, A A Neumann, T R Yeager, R R Reddel: Alternative lengthening of telomeres in mammalian cells. Oncogene 21, 598-610 (2002) (Pubitemid 34146260)
138. K L Cann, G Dellaire: Heterochromatin and the DNA damage response: the need to relax. Biochem Cell Biol 89, 45-60 (2011)
139. S A Martin, M Hewish, C J Lord, A Ashworth: Genomic instability and the selection of treatments for cancer. J Pathol 220, 281-289 (2010)
140. M Lebel, N C de Souza-Pinto, V A Bohr: Metabolism, genomics, and DNA repair in the mouse aging liver. Curr Gerontol Geriatr Res 2011, 859415 (2011)
141. J McKinnon, K W Caldecott: DNA strand break repair and human genetic disease. Annu Rev Genomics Hum Genet 8, 37-55 (2007)
142. J Cadet, T Douki, J L Ravanat: Oxidatively generated base damage to cellular DNA Free Radic Biol Med 49, 9-21 (2010)
143. A Guainazzi, O D Scharer: Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy. Cell Mol Life Sci 67, 3683-3697 (2010)
144. T B Kryston, A B Georgiev, P Pissis, A G Georgakilas: Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 711, 193-201 (2011)
145. E G Seviour, S Y Lin: The DNA damage response: Balancing the scale between cancer and ageing. Aging 2, 900-907 (2010)
146. C Lengauer, K W Kinzler, B Vogelstein: Genetic instabilities in human cancers. Nature 396, 643-649 (1998) (Pubitemid 29003936)
147. J P Murnane, L Sabatier: Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. Bioessays 26, 1164-1174 (2004) (Pubitemid 39536612)
148. P Hasty: Is NHEJ a tumor suppressor or an aging suppressor? Cell Cycle 7, 1139-1145 (2008) (Pubitemid 351749263)
149. F Al-Ejeh, R Kumar, A Wiegmans, S R Lakhani, M P Brown, K K Khanna: Harnessing the complexity of DNAdamage response pathways to improve cancer treatment outcomes. Oncogene 29, 6085-6098 (2010)
150. J W Harper, S J Elledge: The DNA damage response: ten years after. Mol Cell 28, 739-745 (2007) (Pubitemid 350217064)
151. J Campisi: Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513-522 (2005) (Pubitemid 40269765)
152. A Beliveau, P Yaswen: Soothing the watchman: telomerase reduces the p53-dependent cellular stress response. Cell Cycle 6, 1284-1287 (2007) (Pubitemid 47327957)
153. H Vaziri: Critical telomere shortening regulated by the ataxia-telangiectasia gene acts as a DNA damage signal leading to activation of p53 protein and limited life-span of human diploid fibroblasts. A review. Biochemistry, 62, 1306-1310 (1997) (Pubitemid 127665920)
154. E L Denchi, T de Lange: Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 448, 1068-1071 (2007) (Pubitemid 47345583)
155. D Hockemeyer, J P Daniels, H Takai, T de Lange: Recent expansion of the telomeric complex in rodents: Two distinct POT1 proteins protect mouse telomeres. Cell 126, 63-77 (2006)
156. T De Lange: Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol 70, 197-204 (2005) (Pubitemid 44124872)
157. S Maser, R A DePinho: Connecting chromosomes, crisis, and cancer. Science 297, 565-569 (2002)
158. T Davoli, E L Denchi, T de Lange: Persistent telomere damage induces bypass of mitosis and tetraploidy. Cell 141, 81-93 (2010)
159. E Michishita, K Nakabayashi, H Ogino, T Suzuki, M Fujii, D Ayusawa: DNA topoisomerase inhibitors induce reversible senescence in normal human fibroblasts. Biochem Biophys Res Commun 253, 667-671 (1998) (Pubitemid 29039200)
160. D A Gewirtz, S E Holt, L W Elmore: Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol 76, 947-957 (2008)
161. C C Chiu, C H Li, M W Ung, T S Fuh, W L Chen, K Fang: Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non small cell lung cancer cells. Cancer Lett 223, 249-258 (2005) (Pubitemid 40723603)
162. Z Han, W Wei, S Dunaway, J W Darnowski, P Calabresi, J Sedivy, E A Hendrickson, K V Balan, P Pantazis, J H Wyche: Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem 277, 17154-17160 (2002) (Pubitemid 34967748)
163. R S Roberson, S J Kussick, E Vallieres, S Y Chen, D Y Wu: Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 65, 2795-2803 (2005) (Pubitemid 40490082)
164. W Zhao, Z X Lin, Z Q Zhang: Cisplatin-induced premature senescence with concomitant reduction of gap junctions in human fibroblasts. Cell Res 14, 60-66 (2004) (Pubitemid 43231831)
165. H Cheng, Z Y Wu, T Xia, Q Y Hu, H F Hong, Q Y Mai, J L Zheng: Effects of cisplatin on telomerase activity of human choroidal melanoma cells. Zhonghua Yan Ke Za Zhi 44, 705-710 (2008)
166. Vernier, V Bourdeau, M F Gaumont-Leclerc, O Moiseeva, V Begin, F Saad, A M Mes-Masson, G Ferbeyre: Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev 25, 41-50 (2011)
167. Z Novakova, S Hubackova, M Kosar, L Janderova-Rossmeislova, J Dobrovolna, P Vasicova, M Vancurova, Z Horejsi, P Hozak, J Bartek, Z Hodny: Cytokine expression and signaling in drug-induced cellular senescence. Oncogene 29, 273-284 (2010)
168. Z Hodny, S Hubackova, J Bartek: Cytokines shape chemotherapy-induced and 'bystander' senescence. Aging, 2, 375-376 (2010)
169. S Hubackova, Z Novakova, K Krejcikova, M Kosar, J Dobrovolna, P Duskova, H Hanzlikova, M Vancurova, P Barath, J Bartek, Z Hodny: Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle 9, 3085-3099 (2010)
170. F Mbeunkui, D J Johann, Jr.: Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63, 571-582 (2009)
171. J B Konopka, S M Watanabe, J W Singer, S J Collins, O N Witte: Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci U S A 82, 1810-1814 (1985) (Pubitemid 15085267)
172. C M Croce: Oncogenes and cancer. N Engl J Med 358, 502-511 (2008) (Pubitemid 351185806)
173. Y Tsujimoto, J Gorham, J Cossman, E Jaffe, C M Croce: The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229, 1390-1393 (1985) (Pubitemid 16222379)
174. L R Finger, R C Harvey, R C Moore, L C Showe, C M Croce: A common mechanism of chromosomal translocation in T-and B-cell neoplasia. Science 234, 982-985 (1986) (Pubitemid 17193020)
175. R F Newbold, R W Overell: Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304, 648-651 (1983) (Pubitemid 13035507)
176. M Elgendy, C Sheridan, G Brumatti, S J Martin: Oncogenic ras-induced expression of Noxa and Beclin-1 rootes autophagic cell death and limits clonogenic survival. Mol Cell 42, 23-35 (2011)
177. D X Mason, T J Jackson, A W Lin: Molecular signature of oncogenic ras-induced senescence. Oncogene 23, 9238-9246 (2004) (Pubitemid 40069694)
178. C Michaloglou, L C Vredeveld, M S Soengas, C Denoyelle, T Kuilman, C M van der Horst, D M Majoor, J W Shay, W J Mooi, D S Peeper: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005) (Pubitemid 41117276)
179. L A Carragher, K R Snell, S M Giblett, V S Aldridge, B Patel, S J Cook, D J Winton, R Marais, C A Pritchard: V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med 2, 458-471 (2010)
180. D Zhuang, S Mannava, V Grachtchouk, W H Tang, S Patil, J A Wawrzyniak, A E Berman, T J Giordano, E V Prochownik, M S Soengas, M A Nikiforov: C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 27, 6623-6634 (2008)
181. J van Riggelen, D W Felsher: Myc and a Cdk2 senescence switch. Nat Cell Biol 12, 7-9 (2010)
182. L S Steelman, W H Chappell, S L Abrams, R C Kempf, J Long, P Laidler, S Mijatovic, D Maksimovic-Ivanic, F Stivala, M C Mazzarino, M Donia, P Fagone, G Malaponte, F Nicoletti, M Libra, M Milella, A Tafuri, A Bonati, J Basecke, L Cocco, C Evangelisti, A M Martelli, G Montalto, M Cervello, J A McCubrey: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 3, 192-222 (2011)
183. T. Minamino, H Miyauchi, K Tateno, T Kunieda, I Komuro: Akt-induced cellular senescence: implication for human disease. Cell Cycle 3, 449-451 (2004) (Pubitemid 40278235)
184. T Eilon, I Barash: Forced activation of Stat5 subjects mammary epithelial cells to DNA damage and preferential induction of the cellular response mechanism during proliferation. J Cell Physiol 226, 616-26 (2011)
185. G P Dimri, K Itahana, M Acosta, J Campisi: Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol 20, 273-285 (2000) (Pubitemid 30002569)
186. E Lazzerini Denchi, C Attwooll, D Pasini, K Helin: Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 25, 2660-2672 (2005) (Pubitemid 40381630)
187. A Kilbey, A Terry, E R Cameron, J C Neil: Oncogene-induced senescence: an essential role for Runx. Cell Cycle 7, 2333-2340 (2008)
188. L R Borlado, J Mendez: CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis 29, 237-243 (2008) (Pubitemid 351359661)
189. Rillalonga-Planells, L Coll-Mulet, F Martinez-Soler, E Castano, J J Acebes, P Gimenez-Bonafe, J Gil, A Tortosa: Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 6, e18588 (2011)
190. A Takahashi, N Ohtani, E Hara: Irreversibility of cellular senescence: dual roles of p16INK4a/Rb-pathway in cell cycle control. Cell Div 2, 10 (2007)
191. A Shamma, Y Takegami, T Miki, S Kitajima, M Noda, T Obara, T Okamoto and C Takahashi: Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell 15, 255-269 (2009)
192. A Schmitt, J S Fridman, M Yang, S Lee, E Baranov, R M Hoffman, S W Lowe: A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346 (2002) (Pubitemid 34606876)
193. K Vijayachandra, W Higgins, J Lee, A Glick: Induction of p16ink4a and p19ARF by TGFbeta1 contributes to growth arrest and senescence response in mouse keratinocytes. Mol Carcinog 48, 181-186 (2009)
194. S Kagawa, T Fujiwara, Y Kadowaki, T Fukazawa, R Sok-Joo, J A Roth, N Tanaka: Overexpression of the p21 sdi1 gene induces senescence-like state in human cancer cells: implication for senescence-directed molecular therapy for cancer. Cell Death Differ 6, 765-772 (1999) (Pubitemid 29425387)
195. J Y Kang, J J Kim, S Y Jang, Y S Bae: The p53-p21(Cip1/WAF1) pathway is necessary for cellular senescence induced by the inhibition of protein kinase CKII in human colon cancer cells. Mol Cells 28, 489-494 (2009)
196. J Fuxe, G Akusjarvi, H M Goike, G Roos, V P Collins, R F Pettersson: Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A Cell Growth Differ 11, 373-384 (2000) (Pubitemid 30619565)
197. S Courtois-Cox, S M Genther Williams, E E Reczek, B W Johnson, L T McGillicuddy, C M Johannessen, P E Hollstein, M MacCollin, K Cichowski: A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10, 459-472 (2006) (Pubitemid 44872980)
198. H Zhao, J Dupont, S Yakar, M Karas, D LeRoith: PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23, 786-794 (2004) (Pubitemid 38241279)
199. M Baba, S Hirai, S Kawakami, T Kishida, N Sakai, S Kaneko, M Yao, T Shuin, Y Kubota, M Hosaka, S Ohno: Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth. Oncogene 20, 2727-2736 (2001) (Pubitemid 32549830)
200. C Bastian, P E LeBoit, D Pinkel: Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 157, 967-972 (2000) (Pubitemid 32109388)
201. M Pollock, U L Harper, K S Hansen, L M Yudt, M Stark, C M Robbins, T Y Moses, G Hostetter, U Wagner, J Kakareka, G Salem, T Pohida, P Heenan, P Duray, O Kallioniemi, N K Hayward, J M Trent, P S Meltzer: High frequency of BRAF mutations in nevi. Nat Genet 33, 19-20 (2003) (Pubitemid 36068675)
202. X P Zhou, O Gimm, H Hampel, T Niemann, M J Walker, C Eng: Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157, 1123-1128 (2000)
203. S Courtois-Cox, S L Jones, K Cichowski: Many roads lead to oncogene-induced senescence. Oncogene 27, 2801-2809 (2008) (Pubitemid 351620451)
204. E C Chu, A S Tarnawski: PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 10, RA235-RA241 (2004) (Pubitemid 39424480)
205. S Anai, S Goodison, K Shiverick, K Iczkowski, M Tanaka, C J Rosser: Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Hum Gene Ther 17, 975-984 (2006) (Pubitemid 46076739)
206. D R Carrasco, T Fenton, K Sukhdeo, M Protopopova, M Enos, M J You, D Di Vizio, C Nogueira, J Stommel, G S Pinkus, C Fletcher, J L Hornick, W K Cavenee, F B Furnari, R A Depinho: The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell 9, 379-390 (2006) (Pubitemid 43668730)
207. C Nardella, J G Clohessy, A Alimonti, P P Pandolfi: Prosenescence therapy for cancer treatment. Nat Rev Cancer 11, 503-511 (2011)
208. A Carracedo, A Alimonti, P P Pandolfi: PTEN level in tumor suppression: how much is too little? Cancer Res 71, 629-633 (2011)
209. I U Ali: Gatekeeper for endometrium: the PTEN tumor suppressor gene. J Natl Cancer Inst 92, 861-863 (2000) (Pubitemid 30429187)
210. T Andjelkovic, J Bankovic, J Stojsic, V Milinkovic, A Podolski-Renic, S Ruzdijic, N Tanic: Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl Res 157, 19-28 (2011)
211. S Bandyopadhyay, S K Pai, S Hirota, S Hosobe, T Tsukada, K Miura, Y Takano, K Saito, T Commes, D Piquemal, M Watabe, S Gross, Y Wang, J Huggenvik, K Watabe: PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer. Cancer Res 64, 7655-7660 (2004) (Pubitemid 39446890)
212. T A Bismar, M Yoshimoto, R T Vollmer, Q Duan, M Firszt, J Corcos, J A Squire: PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 107, 477-485 (2011)
213. Y G Wen, Q Wang, C Z Zhou, G Q Qiu, Z H Peng, H M Tang: Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 24, 89-95 (2010)
214. J. Bloom, M Pagano: Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 13, 41-47 (2003) (Pubitemid 36269179)
215. K I Nakayama, K Nakayama: Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 16, 323-333 (2005)
216. M Gstaiger, R Jordan, M Lim, C Catzavelos, J Mestan, J Slingerland, W Krek: Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 98, 5043-5048 (2001) (Pubitemid 32397079)
217. C Kim, S Friso, S W Choi: DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging. J Nutr Biochem 20, 917-926 (2009)
218. S F Gilbert: Ageing and cancer as diseases of epigenesis. J Biosci 34, 601-604 (2009)
219. A Breiling, L Sessa, V Orlando: Biology of polycomb and trithorax group proteins. Int Rev Cytol 258, 83-136 (2007) (Pubitemid 46330484)
220. E Vire, C Brenner, R Deplus, L Blanchon, M Fraga, C Didelot, L Morey, A Van Eynde, D Bernard, J M Vanderwinden, M Bollen, M Esteller, L Di Croce, Y de Launoit, F Fuks: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874 (2006) (Pubitemid 43255707)
221. M F Fraga, M Esteller: Epigenetics and aging: the targets and the marks. Trends Genet 23, 413-418 (2007) (Pubitemid 47088010)
222. G Pegoraro, T Misteli: The central role of chromatin maintenance in aging. Aging 1, 1017-1022 (2009)
223. S Gravina, J Vijg: Epigenetic factors in aging and longevity. Pflugers Arch 459, 247-258 (2010)
224. R Satta, E Maloku, A Zhubi, F Pibiri, M Hajos, E Costa, A Guidotti: Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons. Proc Natl Acad Sci U S A 105, 16356-16361 (2008)
225. M E Lleonart, A Artero-Castro, H Kondoh: Senescence induction; a possible cancer therapy. Mol Cancer 8, 3 (2009)
226. M Narita: Cellular senescence and chromatin organization. Br J Cancer 96, 686-691 (2007)
227. R K Lin, H S Hsu, J W Chang, C Y Chen, J T Chen, Y C Wang: Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung Cancer 55, 205-213 (2007)
228. X Han, P Berardi, K Riabowol: Chromatin modification and senescence: linkage by tumor suppressors? Rejuvenation Res 9, 69-76 (2006)
229. R S Pillai: MicroRNA function: multiple mechanisms for a tiny RNA? RNA, 11(12), 1753-61 (2005) (Pubitemid 41720024)
230. K Inoue: MicroRNA function in animal development. Tanpakushitsu Kakusan Koso 52, 197-204 (2007)
231. M Aranha, D M Santos, J M Xavier, W C Low, C J Steer, S Sola, C M Rodrigues: Apoptosis-associated microRNAs are modulated in mouse, rat and human neural differentiation. BMC Genomics 11, 514 (2010)
232. K Lafferty-Whyte, C J Cairney, N B Jamieson, K A Oien, W N Keith: Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms. Biochim Biophys Acta 1792, 341-352 (2009)
233. J Lu, G Getz, E A Miska, E Alvarez-Saavedra, J Lamb, D Peck, A Sweet-Cordero, B L Ebert, R H Mak, A A Ferrando, J R Downing, T Jacks, H R Horvitz, T R Golub: MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005) (Pubitemid 40839735)
234. J S Ross, J A Carlson, G Brock: miRNA: the new gene silencer. Am J Clin Pathol 128, 830-836 (2007) (Pubitemid 350133996)
235. M. Yamakuchi, M Ferlito, C J Lowenstein: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 105, 13421-13426 (2008)
236. H Tazawa, N Tsuchiya, M Izumiya, H Nakagama: Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 104, 15472-15477 (2007) (Pubitemid 47502941)
237. G Zauli, R Voltan, M G di Iasio, R Bosco, E Melloni, M E Sana, P Secchiero: miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 17, 2712-2724 (2011)
238. R Christoffersen, R Shalgi, L B Frankel, E Leucci, M Lees, M Klausen, Y Pilpel, F C Nielsen, M Oren, A H Lund: p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC Cell Death Differ 17, 236-245 (2010)
239. X Zhong, N Li, S Liang, Q Huang, G Coukos and L Zhang: Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem 285, 41961-41971 (2010)
240. X Yang, M Feng, X Jiang, Z Wu, Z Li, M Aau, Q Yu: miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A Genes Dev 23, 2388-23893 (2009)
241. J Noonan, R F Place, D Pookot, S Basak, J M Whitson, H Hirata, C Giardina, R Dahiya: miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28, 1714-24 (2009)
242. M Voorhoeve, C le Sage, M Schrier, A J Gillis, H Stoop, R Nagel, Y P Liu, J van Duijse, J Drost, A Griekspoor, E Zlotorynski, N Yabuta, G De Vita, H Nojima, L H Looijenga, R Agami: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124, 1169-1181 (2006)
243. H Hermeking: The miR-34 family in cancer and apoptosis. Cell Death Differ 17, 193-199 (2009)
244. K Kumamoto, E A Spillare, K Fujita, I Horikawa, T Yamashita, E Appella, M Nagashima, S Takenoshita, J Yokota, C C Harris: Nutlin-3a activates p53 to both downregulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68, 3193-3203 (2008)
245. S Mitomo, C Maesawa, S Ogasawara, T Iwaya, M Shibazaki, A Yashima-Abo, K Kotani, H Oikawa, E Sakurai, N Izutsu, K Kato, H Komatsu, K Ikeda, G Wakabayashi, T Masuda: Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 99, 280-286 (2008) (Pubitemid 351228481)
246. D Y Lee, Z Deng, C H Wang, B B Yang: MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 104, 20350-20355 (2007)
247. S Venkataraman, I Alimova, R Fan, P Harris, N Foreman, R Vibhakar: MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One 5, e10748 (2010)
248. E Ferretti, E De Smaele, A Po, L Di Marcotullio, E Tosi, M S Espinola, C Di Rocco, R Riccardi, F Giangaspero, A Farcomeni, I Nofroni, P Laneve, U Gioia, E Caffarelli, I Bozzoni, I Screpanti, A Gulino: MicroRNA profiling in human medulloblastoma. Int J Cancer 124, 568-577 (2009)
249. Y Zhang, T Chao, R Li, W Liu, Y Chen, X Yan, Y Gong, B Yin, B Qiang, J Zhao, J Yuan, X Peng: MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med 87, 43-51 (2009)
250. V Havelange, N Stauffer, C C Heaphy, S Volinia, M Andreeff, G Marcucci, C M Croce, R Garzon: Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer (2011)
251. P. Medawar: UNSOLVED problem of biology. Med J Aust 1, 854-855 (1953)
252. K A Hughes: Mutation and the evolution of ageing: from biometrics to system genetics. Philos Trans R Soc Lond B Biol Sci 365, 1273-1279 (2010)
253. P D Williams, T Day: Antagonistic pleiotropy, mortality source interactions, and the evolutionary theory of senescence. Evolution 57, 1478-1488 (2003) (Pubitemid 36953637)
254. M Rose. Evolutionary Biology of Aging. New York: Oxford University Press (1991)
255. P Achinstein. Observation and theory. In: A Companion to the Philosophy of Science. Ed: W Newton-Smith, M A Malden. Blackwell Publishing Ltd (2000)
256. L A K Milewski: The evolution of ageing. Bioscience Horizons 3, 77-84 (2010)
257. J M Sedivy: Telomeres limit cancer growth by inducing senescence: long-sought in vivo evidence obtained. Cancer Cell 11, 389-391 (2007) (Pubitemid 46670082)
258. P A Muller, K H Vousden, J C Norman: p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192, 209-218 (2011)
259. E M Pinto, R C Ribeiro, B C Figueiredo, G P Zambetti: TP53-associated pediatric malignancies. Genes Cancer 2, 485-490 (2011)
260. M F Haussmann, D W Winkler, C E Huntington, I C Nisbet, C M Vleck: Telomerase activity is maintained throughout the lifespan of long-lived birds. Exp Gerontol 42, 610-618 (2007) (Pubitemid 46756106)
261. V Gorbunova, A Seluanov: Coevolution of telomerase activity and body mass in mammals: from mice to beavers. Mech Ageing Dev 130, 3-9 (2009)
262. A Tomas-Loba, I Flores, P J Fernandez-Marcos, M L Cayuela, A Maraver, A Tejera, C Borras, A Matheu, P Klatt, J M Flores, J Vina, M Serrano, M A Blasco: Telomerase reverse transcriptase delays aging in cancerresistant mice. Cell 135, 609-622 (2008)
263. D Gilley, H Tanaka, B S Herbert: Telomere dysfunction in aging and cancer. Int J Biochem Cell Biol 37, 1000-1013 (2005) (Pubitemid 40311742)
264. T B Kirkwood: Asymmetry and the origins of ageing. Mech Ageing Dev 126, 533-534 (2005) (Pubitemid 40461952)
265. G M Wahl, A M Carr: The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3, E277-E286 (2001) (Pubitemid 33130452)
266. M Murga, O Fernandez-Capetillo: Genomic instability: on the birth and death of cancer. Clin Transl Oncol 9, 216-220 (2007)